Your browser doesn't support javascript.
loading
Dysfunctional and Dysregulated Nitric Oxide Synthases in Cardiovascular Disease: Mechanisms and Therapeutic Potential.
Roy, Roman; Wilcox, Joshua; Webb, Andrew J; O'Gallagher, Kevin.
Affiliation
  • Roy R; Cardiovascular Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
  • Wilcox J; Cardiovascular Department, Guy's and St. Thomas' NHS Foundation Trust, London SE1 7EH, UK.
  • Webb AJ; Department of Clinical Pharmacology, British Heart Foundation Centre, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London SE1 7EH, UK.
  • O'Gallagher K; Cardiovascular Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Int J Mol Sci ; 24(20)2023 Oct 15.
Article in En | MEDLINE | ID: mdl-37894881
Nitric oxide (NO) plays an important and diverse signalling role in the cardiovascular system, contributing to the regulation of vascular tone, endothelial function, myocardial function, haemostasis, and thrombosis, amongst many other roles. NO is synthesised through the nitric oxide synthase (NOS)-dependent L-arginine-NO pathway, as well as the nitrate-nitrite-NO pathway. The three isoforms of NOS, namely neuronal (NOS1), inducible (NOS2), and endothelial (NOS3), have different localisation and functions in the human body, and are consequently thought to have differing pathophysiological roles. Furthermore, as we continue to develop a deepened understanding of the different roles of NOS isoforms in disease, the possibility of therapeutically modulating NOS activity has emerged. Indeed, impaired (or dysfunctional), as well as overactive (or dysregulated) NOS activity are attractive therapeutic targets in cardiovascular disease. This review aims to describe recent advances in elucidating the physiological role of NOS isoforms within the cardiovascular system, as well as mechanisms of dysfunctional and dysregulated NOS in cardiovascular disease. We then discuss the modulation of NO and NOS activity as a target in the development of novel cardiovascular therapeutics.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases Limits: Humans Language: En Journal: Int J Mol Sci Year: 2023 Document type: Article Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases Limits: Humans Language: En Journal: Int J Mol Sci Year: 2023 Document type: Article Country of publication: Switzerland